0001770069-19-000003.txt : 20190322 0001770069-19-000003.hdr.sgml : 20190322 20190322072752 ACCESSION NUMBER: 0001770069-19-000003 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190322 DATE AS OF CHANGE: 20190322 EFFECTIVENESS DATE: 20190322 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alvarado Therapeutics, Inc. CENTRAL INDEX KEY: 0001770069 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-334440 FILM NUMBER: 19698385 BUSINESS ADDRESS: STREET 1: 75 OXBOW ROAD CITY: CONCORD STATE: MA ZIP: 01742 BUSINESS PHONE: 919-641-8778 MAIL ADDRESS: STREET 1: 75 OXBOW ROAD CITY: CONCORD STATE: MA ZIP: 01742 D/A 1 primary_doc.xml X0708 D/A LIVE 0001770069 Alvarado Therapeutics, Inc. 501 2nd Street San Francisco CA CALIFORNIA 94107 919-641-8778 DELAWARE None None Corporation true 2018 Christopher A Kroeger c/o Alvarado Therapeutics, Inc. 501 2nd Street San Francisco CA CALIFORNIA 94107 Executive Officer Director George Pavlov c/o Alvarado Therapeutics, Inc. 501 2nd Street San Francisco CA CALIFORNIA 94107 Director Robert Malenka c/o Alvarado Therapeutics, Inc. 501 2nd Street San Francisco CA CALIFORNIA 94107 Director James Lillie c/o Alvarado Therapeutics, Inc. 501 2nd Street San Francisco CA CALIFORNIA 94107 Executive Officer Peter A Bisgaard c/o Alvarado Therapeutics, Inc. 501 2nd Street San Francisco CA CALIFORNIA 94107 Director Jonathan Gillis c/o Alvarado Therapeutics, Inc. 501 2nd Street San Francisco CA CALIFORNIA 94107 Executive Officer Biotechnology Decline to Disclose 06b true 0001770069-19-000002 2019-02-22 false true true The underlying shares of common stock issuable upon conversion. false 0 5000000 5000000 0 false 2 0 0 0 false Alvarado Therapeutics, Inc. /s/ Christopher A. Kroeger Christopher A. Kroeger Chief Executive Officer 2019-03-21